Chipscreen Biosciences, Ltd. is running a clinical trial to test a drug called Chiauranib to treat non-Hodgkin’s Lymphoma. Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin’s lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
The drug is Chiauranib.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin’s Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study|
|Actual Study Start Date :||May 9, 2017|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||May 2019|
For enrollment please visit www.clinicaltrials.gov.